InDaily InDaily

Support independent Journalism Donate Subscribe
Support independent journalism

Opinion

Vaccine unlikely to be cure-all so we must plan to safeguard public health

Opinion

With early evidence showing first-generation vaccines help suppress COVID-19-related illness but are unlikely to prevent the actual infection, other public health measures must continue for the foreseeable future, argue Tania Sorrell, Ian Frazer and Ingrid Scheffer.

 

 

Print article

By any global measure, Australia’s response to the COVID pandemic has been a spectacular success. Public health measures introduced by state, territory and federal governments, with the help of the Australian community, have significantly reduced the impact of the disease.

The response has come at significant economic and broader health costs, however. As the second wave in Victoria showed, success can be fragile. The strong measures needed to regain control of an outbreak bring unavoidable social and financial harms.

To avoid another surge in case numbers, it is crucial that we plan for the coming months as we head into 2021.

Emerging evidence suggests the first-generation vaccines currently in clinical trials have a good chance of preventing SARS-CoV-2 related illness, but they are less likely to prevent infection with the virus altogether. This means it is unlikely current vaccines will adequately suppress viral transmission.

This means there’s not yet a “silver bullet” that can return Australia and the world to pre-COVID normality. Instead, we anticipate a scenario in which vaccines, antiviral therapies and other tools that become available will help reduce COVID-associated hospitalisation and deaths.

Suite of measures

To be optimally effective, vaccines must be considered as part of a wider suite of measures. The advent of vaccines does not mean we can now weaken, much less abandon, the other public health methods developed and practised in their absence.

In a new review of likely next developments, published by the Australian Academy of Health and Medical Sciences, we found that for the foreseeable future, national control of the pandemic will need to be driven by:

The top priorities

In our review, we identify four areas for priority attention, subdivided into 15 specific actions, to ensure Australia is equipped to build a system that is robust and yet flexible enough to continue its successful management of the pandemic – at home and abroad.

We need to create effective systems and capabilities to develop, manufacture and distribute vaccines, treatments and diagnostic tests.

We must monitor the health impacts of COVID within Australia, and the acceptability, safety, efficacy and uptake of vaccines, treatments and other interventions.

We have to enable ethical and equitable rollout of vaccines, treatments and other interventions.

And finally, we must be able to respond to the evolution of the pandemic through a readiness to modify public health measures appropriately. Frequent hand-washing and cough etiquette must be sustained. Strategies such as hotel quarantine for overseas travellers, and tightening of restrictions during periods of community COVID transmission, are major tools that have shaped Australia’s enviable achievement to date and will doubtless be needed again.

This might mean periodic resumptions of strong social distancing, limits on gatherings (particularly indoors), safe use of public transport, wearing of masks, and isolation.

Australia’s capacity to deliver effective public health programs, together with our world-class research and innovation sector, mean we are well placed to execute this agenda.

Doing so successfully will bring additional, longer-term benefits, through enhancing our ability to respond to future pandemics.

Tania Sorrell, Professor, Clinical Infectious Diseases, Director, Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney; Ian Frazer, Chair, Medical Advisory Committee, Australian Cancer Research Foundation; Director, Diamantina Institute for Cancer Immunology and Metabolic Medicine, The University of Queensland, and Ingrid Scheffer, Director of Paediatrics, Austin Health; NHMRC Practitioner Fellow; Senior Principal Research Fellow, The Florey Institute; Professor of Paediatric Neurology Research, University of Melbourne

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The Conversation

Make a comment View comment guidelines

Make your contribution to independent news

A donation of any size to InDaily goes directly to helping our journalists uncover the facts. South Australia needs more than one voice to guide it forward, and we’d truly appreciate your contribution. Please click below to donate to InDaily.

Donate here
Powered by PressPatron

More Opinion stories

Loading next article